A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Degarelix (Primary) ; Letrozole; Triptorelin
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms TREND
- 07 Jun 2017 Biomarkers information updated
- 29 May 2017 Planned End Date changed from 1 Sep 2021 to 1 Aug 2017.
- 29 May 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Aug 2017.